KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Equity Income (2020 - 2023)

Historic Equity Income for BeOne Medicines (ONC) over the last 4 years, with Q4 2023 value amounting to -$3.9 million.

  • BeOne Medicines' Equity Income rose 2928.53% to -$3.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$16.2 million, marking a year-over-year increase of 2625.48%. This contributed to the annual value of -$16.2 million for FY2023, which is 2625.48% up from last year.
  • Latest data reveals that BeOne Medicines reported Equity Income of -$3.9 million as of Q4 2023, which was up 2928.53% from -$10.1 million recorded in Q3 2023.
  • Over the past 5 years, BeOne Medicines' Equity Income peaked at $23.2 million during Q3 2021, and registered a low of -$17.0 million during Q1 2022.
  • Moreover, its 4-year median value for Equity Income was -$2.4 million (2021), whereas its average is -$1.4 million.
  • Examining YoY changes over the last 5 years, BeOne Medicines' Equity Income showed a top increase of 231364.5% in 2021 and a maximum decrease of 1166521.74% in 2021.
  • BeOne Medicines' Equity Income (Quarter) stood at $1.9 million in 2020, then tumbled by 614.79% to -$9.5 million in 2021, then soared by 41.44% to -$5.6 million in 2022, then grew by 29.29% to -$3.9 million in 2023.
  • Its Equity Income was -$3.9 million in Q4 2023, compared to -$10.1 million in Q3 2023 and -$2.0 million in Q2 2023.